person · Reporting owner
Senner Christopher J.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EXELIXIS, INC.EXEL · Entity 3386 | EVP and CFO | May 15, 2026 | May 19, 2026 |
| Quince Therapeutics, Inc.QNCX · Entity 7403 | Director | June 11, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EXELIXIS, INC.
Report date May 15, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 952,317 |
Last balance in matching sequence
After 2026-05-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-05-15 · Tax withholding · Disposed 40,892 · Balance 987,218 F1: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units ("RSUs") awarded on March 4, 2022, April 3, 2023, February 23, 2024, and February 26, 2025. F2: Includes 403,915 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and the performance-based restricted stock unit award granted to the Reporting Person on March 31, 2025 ("One-Time Award PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each One-Time Award PSU represents a contingent right to receive one share of Common Stock. Row 2 · 2026-05-18 · Sale · Disposed 34,901 · Balance 952,317 F3: Represents the weighted average sales price. The shares of Common Stock were sold in multiple transactions at prices ranging from $50.00 to $50.07. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. F2: Includes 403,915 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and the performance-based restricted stock unit award granted to the Reporting Person on March 31, 2025 ("One-Time Award PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each One-Time Award PSU represents a contingent right to receive one share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) | 2,723 |
Reported balance
Holding disclosure · report date 2026-05-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,723 F4: Represents shares of Common Stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of May 14, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units ("RSUs") awarded on March 4, 2022, April 3, 2023, February 23, 2024, and February 26, 2025.
F2: Includes 403,915 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and the performance-based restricted stock unit award granted to the Reporting Person on March 31, 2025 ("One-Time Award PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each One-Time Award PSU represents a contingent right to receive one share of Common Stock.
F3: Represents the weighted average sales price. The shares of Common Stock were sold in multiple transactions at prices ranging from $50.00 to $50.07. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
F4: Represents shares of Common Stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of May 14, 2026.
Quince Therapeutics, Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2036-06-11 | Direct | 2,700 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 2,700 · Balance 2,700 F1: 100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 21:51 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantDirector Stock Option (Right to Buy) · Derivative | 2,700 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0000912282-26-000830 · form4.xml · derivative · entry 1 Senner Christopher J. · CIK 0001648367 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,700 Underlying: Common Stock · 2,700 shares Expires 2036-06-11 F1 · derivative.exercise_date: 100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date. Read SEC document |
| May 18, 2026 Filed May 19, 2026 22:58 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 34,901 | $50.00 | $1,745,050.00 |
DisclosureSEC source: 0000939767-26-000067 · wk-form4_1779231521.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 952,317 F3 · price: Represents the weighted average sales price. The shares of Common Stock were sold in multiple transactions at prices ranging from $50.00 to $50.07. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. F2 · balance_after: Includes 403,915 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and the performance-based restricted stock unit award granted to the Reporting Person on March 31, 2025 ("One-Time Award PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each One-Time Award PSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| May 15, 2026 Filed May 19, 2026 22:58 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 40,892 | $51.10 | $2,089,581.20 |
DisclosureSEC source: 0000939767-26-000067 · wk-form4_1779231521.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 987,218 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units ("RSUs") awarded on March 4, 2022, April 3, 2023, February 23, 2024, and February 26, 2025. F2 · balance_after: Includes 403,915 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and the performance-based restricted stock unit award granted to the Reporting Person on March 31, 2025 ("One-Time Award PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each One-Time Award PSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| February 26, 2026 Filed Mar 3, 2026 00:59 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 52,018 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-26-000036 · wk-form4_1772499569.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,028,110 F1 · date: Represents shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon the vesting of restricted stock units ("RSUs"). The RSUs were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The RSUs will vest as to 1/4th of the original number of shares subject to the RSU award on May 15, 2027 and thereafter as to 1/4th of the original number of shares subject to the RSU award on each May 15th until fully vested. F1 · shares: Represents shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon the vesting of restricted stock units ("RSUs"). The RSUs were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The RSUs will vest as to 1/4th of the original number of shares subject to the RSU award on May 15, 2027 and thereafter as to 1/4th of the original number of shares subject to the RSU award on each May 15th until fully vested. F2 · balance_after: Includes 479,708 shares of Common Stock that will be issued to the Reporting Person upon vesting of RSUs and the performance-based restricted stock unit award granted to the Reporting Person on March 31, 2025 ("One-Time Award PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each One-Time Award PSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 01:49 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 30,617 | $43.67 | $1,337,044.39 |
DisclosureSEC source: 0000939767-26-000028 · wk-form4_1771465767.xml · nonDerivative · entry 3 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 976,092 F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $43.66 to $43.78. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. F2 · balance_after: Includes 427,690 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs") and PSUs granted to the Reporting Person on March 31, 2025 ("One-Time Award PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each One-Time Award PSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| February 15, 2026 Filed Feb 19, 2026 01:49 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 35,870 | $43.92 | $1,575,410.40 |
DisclosureSEC source: 0000939767-26-000028 · wk-form4_1771465767.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,006,709 F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on March 4, 2022, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on January 16, 2025. F2 · balance_after: Includes 427,690 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs") and PSUs granted to the Reporting Person on March 31, 2025 ("One-Time Award PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each One-Time Award PSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| February 13, 2026 Filed Feb 19, 2026 01:49 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 34,278 | $43.00 | $1,473,954.00 |
DisclosureSEC source: 0000939767-26-000028 · wk-form4_1771465767.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,042,579 F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $43.00 to $43.04. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4. F2 · balance_after: Includes 427,690 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs") and PSUs granted to the Reporting Person on March 31, 2025 ("One-Time Award PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each One-Time Award PSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| January 15, 2026 Filed Jan 17, 2026 00:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 40,459 | $45.23 | $1,829,960.57 |
DisclosureSEC source: 0000939767-26-000004 · wk-form4_1768608160.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,076,857 F4 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of the PSUs awarded on April 3, 2023, for which the Committee certified that Exelixis, Inc. had achieved certain performance criteria on January 15, 2026. F3 · balance_after: Includes 494,177 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs") and PSUs granted to the Reporting Person on March 31, 2025 ("One-Time Award PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each One-Time Award PSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| January 15, 2026 Filed Jan 17, 2026 00:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 149,474 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-26-000004 · wk-form4_1768608160.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,117,316 F1 · date: On April 3, 2023, the Reporting Person was granted a performance-based restricted stock unit award ("PSU") under the Exelixis, Inc. 2017 Equity Incentive Plan covering 85,414 shares of common stock (such shares, the "Target Shares"). The PSU generally vests as follows: (i) 50% of the eligible Target Shares vest upon the Compensation Committee's (the "Committee") certification of achievement of certain performance criteria; and (ii) 50% of the eligible Target Shares vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. In addition, the PSU provides for vesting of up to a maximum of 175% of the Target Shares depending on the timing and level of achievement of the performance criteria provided for under the PSU. F2 · shares: On January 15, 2026, the Committee determined that certain performance criteria had been achieved, resulting in the Reporting Person's eligibility to vest up to 175% of the Target Shares subject to the PSU (such shares, the "Achieved Shares"). Accordingly, the Committee's certification on January 15, 2026 resulted in the immediate vesting of 50% of the Achieved Shares, and the remaining 50% of the Achieved Shares will vest on February 15, 2027, subject to the Reporting Person's continuous service through that date. F3 · balance_after: Includes 494,177 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs") and PSUs granted to the Reporting Person on March 31, 2025 ("One-Time Award PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each One-Time Award PSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| January 02, 2026 Filed Jan 21, 2026 23:14 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantDirector Stock Option (Right to Buy) · Derivative | 21,810 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0000912282-26-000089 · form4.xml · derivative · entry 1 Senner Christopher J. · CIK 0001648367 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,810 Underlying: Common Stock · 21,810 shares Expires 2036-01-02 F1 · derivative.exercise_date: The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2026 provided for under the Issuer's Outside Director Compensation Policy. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 21:36 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantDirector Stock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0000912282-25-000621 · form4.xml · derivative · entry 1 Senner Christopher J. · CIK 0001648367 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares subject to the option shall vest 100% on the one-year anniversary of the grant date. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy. Read SEC document |
| May 16, 2025 Filed May 17, 2025 00:58 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 100,000 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0000939767-25-000081 · wk-form4_1747443475.xml · derivative · entry 5 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2025-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 100,000 shares of Common Stock, became fully exercisable on September 10, 2022. Read SEC document |
| May 16, 2025 Filed May 17, 2025 00:58 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 100,000 | $46.00 | $4,600,000.00 |
DisclosureSEC source: 0000939767-25-000081 · wk-form4_1747443475.xml · nonDerivative · entry 3 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 967,842 F2 · balance_after: Includes 419,440 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| May 16, 2025 Filed May 17, 2025 00:58 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 100,000 | $18.80 | $1,880,000.00 |
DisclosureSEC source: 0000939767-25-000081 · wk-form4_1747443475.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,067,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes 419,440 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| May 15, 2025 Filed May 17, 2025 00:58 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 41,422 | $44.65 | $1,849,492.30 |
DisclosureSEC source: 0000939767-25-000081 · wk-form4_1747443475.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 967,842 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units ("RSUs") awarded on March 4, 2021, March 4, 2022, April 3, 2023, and February 23, 2024. F2 · balance_after: Includes 419,440 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| March 31, 2025 Filed Mar 31, 2025 23:42 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 170,009 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-25-000050 · wk-form4_1743464565.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,009,264 F1 · shares: Represents an award of performance-based restricted stock units (each, a "PSU") that was granted to the Reporting Person on the Transaction Date pursuant to the 2017 Equity Incentive Plan. Each PSU represents a contingent right to receive one share of Exelixis, Inc. common stock ("Common Stock"). The PSUs vest upon satisfaction of both (i) a performance-based condition requiring the volume-weighted average closing price of the Common Stock to equal or exceed $60 per share for any consecutive 90-calendar-day period during a five-year performance period, and (ii) a service-based condition requiring employment through the fifth anniversary of the grant date (except in the event of certain qualifying terminations of employment). F2 · balance_after: Includes 496,357 shares of Common Stock that will be issued to the Reporting Person upon the vesting of restricted stock units (each, an "RSU") and the PSUs. Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| February 26, 2025 Filed Mar 1, 2025 01:34 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 59,648 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-25-000038 · wk-form4_1740792871.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 839,255 F1 · security: Represents shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. F2 · date: The RSUs were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The RSUs will vest as to 1/4th of the original number of shares subject to the RSU award on May 15, 2026 and thereafter as to 1/4th of the original number of shares subject to the RSU award on each May 15th until fully vested. F3 · balance_after: Includes 326,348 shares of Common Stock that will be issued to the Reporting Person upon vesting of RSUs. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 01:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 29,314 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0000939767-25-000033 · wk-form4_1740618023.xml · derivative · entry 4 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 29,314 shares Expires 2025-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 129,314 shares of Common Stock, became fully exercisable on September 10, 2022. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 01:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 29,314 | $36.14 | $1,059,407.96 |
DisclosureSEC source: 0000939767-25-000033 · wk-form4_1740618023.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 779,607 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $36.11 to $36.21. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. F1 · balance_after: Includes 266,700 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 01:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 29,314 | $18.80 | $551,103.20 |
DisclosureSEC source: 0000939767-25-000033 · wk-form4_1740618023.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 808,921 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 266,700 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 01:32 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 21,591 | $35.00 | $755,685.00 |
DisclosureSEC source: 0000939767-25-000028 · wk-form4_1740015152.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 779,607 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on March 4, 2021, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on January 11, 2024. F2 · balance_after: Includes 266,700 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock.. Read SEC document |
| January 16, 2025 Filed Jan 18, 2025 02:45 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 35,949 | $37.27 | $1,339,819.23 |
DisclosureSEC source: 0000939767-25-000008 · wk-form4_1737168323.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 801,198 F4 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of PSU awarded on March 4, 2022, for which the Committee certified that Exelixis, Inc. had achieved certain performance criteria on January 16, 2025. F3 · balance_after: Includes 306,793 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| January 16, 2025 Filed Jan 18, 2025 02:45 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 132,973 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-25-000008 · wk-form4_1737168323.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 837,147 F1 · date: On March 4, 2022, the Reporting Person was granted a performance-based restricted stock unit award ("PSU") under the Exelixis, Inc. 2017 Equity Incentive Plan covering 75,985 shares of common stock (such shares, the "Target Shares"). The PSU generally vests as follows: (i) 50% of the eligible Target Shares vest upon the Compensation Committee's (the "Committee") certification of achievement of certain performance criteria; and (ii) 50% of the eligible Target Shares vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. In addition, the PSU provides for vesting of up to a maximum of 175% of the Target Shares depending on the timing and level of achievement of the performance criteria provided for under the PSU. F2 · shares: On January 16, 2025, the Committee determined that certain performance criteria had been achieved, resulting in the Reporting Person's eligibility to vest up to 175% of the Target Shares subject to the PSU (such shares, the "Achieved Shares"). Accordingly, the Committee's certification on January 16, 2025 resulted in the immediate vesting of 50% of the Achieved Shares, and 50% of the Achieved Shares will vest on February 15, 2026, subject to the Reporting Person's continuous service through that date. F3 · balance_after: Includes 306,793 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| January 02, 2025 Filed Jan 9, 2025 00:29 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantDirector Stock Option (right to buy) · Derivative | 35,274 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0001415889-25-001160 · form4-01092025_120111.xml · derivative · entry 1 Senner Christopher J. · CIK 0001648367 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,274 Underlying: Common Stock · 35,274 shares Expires 2035-01-02 F1 · derivative.exercise_date: The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the Issuer's Outside Director Compensation Policy. Read SEC document |
| November 15, 2024 Filed Nov 20, 2024 01:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 17,506 | $35.05 | $613,585.30 |
DisclosureSEC source: 0000939767-24-000163 · wk-form4_1732064604.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 704,174 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 11, 2020, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on September 6, 2023. F2 · balance_after: Includes 240,306 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| August 09, 2024 Filed Aug 9, 2024 23:31 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 125,000 | $0.00 Strike: $24.41 | $0.00 |
DisclosureSEC source: 0000939767-24-000123 · wk-form4_1723246304.xml · derivative · entry 4 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2024-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 125,000 shares of Exelixis, Inc. common stock became fully exercisable on October 3, 2021. Read SEC document |
| August 09, 2024 Filed Aug 9, 2024 23:31 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 125,000 | $27.19 | $3,398,750.00 |
DisclosureSEC source: 0000939767-24-000123 · wk-form4_1723246304.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 721,680 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $27.08 to $27.35. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. F1 · balance_after: Includes 272,874 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 09, 2024 Filed Aug 9, 2024 23:31 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 125,000 | $24.41 | $3,051,250.00 |
DisclosureSEC source: 0000939767-24-000123 · wk-form4_1723246304.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 846,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 272,874 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| June 05, 2024 Filed Jun 8, 2024 01:00 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantEmployee Stock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001415889-24-016090 · form4-06082024_010651.xml · derivative · entry 1 Senner Christopher J. · CIK 0001648367 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2034-06-05 F1 · derivative.exercise_date: 100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date. Read SEC document |
| May 15, 2024 Filed May 17, 2024 23:57 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 11,478 | $20.99 | $240,923.22 |
DisclosureSEC source: 0000939767-24-000067 · wk-form4_1715990248.xml · nonDerivative · entry 3 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 721,680 F4 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded April 3, 2023. F2 · balance_after: Includes 272,874 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 15, 2024 Filed May 17, 2024 23:57 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 10,211 | $20.99 | $214,328.89 |
DisclosureSEC source: 0000939767-24-000067 · wk-form4_1715990248.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 733,158 F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded March 4, 2022. F2 · balance_after: Includes 272,874 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 15, 2024 Filed May 17, 2024 23:57 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 8,621 | $20.99 | $180,954.79 |
DisclosureSEC source: 0000939767-24-000067 · wk-form4_1715990248.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 743,369 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded March 4, 2021. F2 · balance_after: Includes 272,874 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 23:58 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 82,121 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-24-000032 · wk-form4_1709078302.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 751,990 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2025 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested. F3 · balance_after: Includes 329,261 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| January 11, 2024 Filed Jan 17, 2024 01:50 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 21,862 | $22.86 | $499,765.32 |
DisclosureSEC source: 0000939767-24-000019 · wk-form4_1705456231.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 669,869 F4 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on January 11, 2024. F3 · balance_after: Includes 247,140 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| January 11, 2024 Filed Jan 17, 2024 01:50 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 80,186 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-24-000019 · wk-form4_1705456231.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 691,731 F1 · date: On March 4, 2021, the Reporting Person was granted a performance-based restricted stock unit award ("PSU") under the Exelixis, Inc. 2017 Equity Incentive Plan covering 64,150 shares of common stock (such shares, the "Target Shares"). The PSU generally vests as follows: (i) 50% of the eligible Target Shares vest upon the Compensation Committee's (the "Committee") certification of achievement of certain performance criteria; and (ii) 50% of the eligible Target Shares vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. In addition, the PSU provides for vesting of up to a maximum of 200% of the Target Shares depending on the timing and level of achievement of the performance criteria provided for under the PSU. F2 · shares: On January 11, 2024, the Committee determined that certain performance criteria had been achieved, resulting in the Reporting Person's eligibility to vest up to 125% of the Target Shares subject to the PSU (such shares, the "Achieved Shares"). Accordingly, the Committee's certification on January 11, 2024 resulted in the immediate vesting of 50% of the Achieved Shares, and 50% of the Achieved Shares will vest on February 15, 2025, subject to the Reporting Person's continuous service through that date. F3 · balance_after: Includes 247,140 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 06, 2023 Filed Sep 9, 2023 01:26 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 17,147 | $22.27 | $381,863.69 |
DisclosureSEC source: 0000939767-23-000106 · wk-form4_1694222798.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 611,545 F4 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on September 6, 2023. F3 · balance_after: Includes 207,047 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 06, 2023 Filed Sep 9, 2023 01:26 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 65,135 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-23-000106 · wk-form4_1694222798.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 628,692 F1 · date: On September 11, 2020, the Reporting Person was granted a performance-based restricted stock unit award ("PSU") under the Exelixis, Inc. 2017 Equity Incentive Plan covering 65,135 shares of common stock (such shares, the "Target Shares"). The PSU generally vests as follows: (i) 50% of the eligible Target Shares vest upon the Compensation Committee's (the "Committee") certification of achievement of certain performance criteria; and (ii) 50% of the eligible Target Shares vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. In addition, the PSU provides for vesting of up to a maximum of 200% of the Target Shares depending on the timing and level of achievement of the performance criteria provided for under the PSU. F2 · shares: On September 6, 2023, the Committee determined that certain performance criteria had been achieved, resulting in the Reporting Person's eligibility to vest up to 150% of the Target Shares subject to the PSU (such shares, the "Achieved Shares"). The Reporting Person had already vested 1/3 of the Achieved Shares as a result of the Committee's certification that certain performance criteria had been achieved on August 3, 2022 and continuous service through August 15, 2023. Accordingly, the Committee's certification on September 6, 2023 resulted in the immediate vesting of 1/3 of the Achieved Shares, and 1/3 of the Achieved Shares will vest on November 15, 2024, subject to the Reporting Person's continuous service through that date. The Reporting Person remains eligible for additional vesting depending on the level and timing of achievement of the performance criteria through December 31, 2024. F3 · balance_after: Includes 207,047 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 15, 2023 Filed Aug 18, 2023 00:19 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 8,074 | $21.51 | $173,671.74 |
DisclosureSEC source: 0000939767-23-000089 · wk-form4_1692317932.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 563,557 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 11, 2020, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on August 3, 2022. F2 · balance_after: Includes 174,479 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 04, 2023 Filed Aug 8, 2023 01:20 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 60,000 | $0.00 Strike: $14.74 | $0.00 |
DisclosureSEC source: 0000939767-23-000084 · wk-form4_1691457604.xml · derivative · entry 7 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2023-09-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2023 Filed Aug 8, 2023 01:20 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 60,000 | $20.68 | $1,240,800.00 |
DisclosureSEC source: 0000939767-23-000084 · wk-form4_1691457604.xml · nonDerivative · entry 4 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 571,631 F1 · balance_after: Includes 190,763 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 04, 2023 Filed Aug 8, 2023 01:20 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 60,000 | $14.74 | $884,400.00 |
DisclosureSEC source: 0000939767-23-000084 · wk-form4_1691457604.xml · nonDerivative · entry 3 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 631,631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 190,763 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 03, 2023 Filed Aug 8, 2023 01:20 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 60,000 | $0.00 Strike: $14.74 | $0.00 |
DisclosureSEC source: 0000939767-23-000084 · wk-form4_1691457604.xml · derivative · entry 6 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2023-09-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 120,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 22, 2020. Read SEC document |
| August 03, 2023 Filed Aug 8, 2023 01:20 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 60,000 | $20.51 | $1,230,600.00 |
DisclosureSEC source: 0000939767-23-000084 · wk-form4_1691457604.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 571,631 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.50 to $20.60. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. F1 · balance_after: Includes 190,763 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 03, 2023 Filed Aug 8, 2023 01:20 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 60,000 | $14.74 | $884,400.00 |
DisclosureSEC source: 0000939767-23-000084 · wk-form4_1691457604.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 631,631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 190,763 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 24, 2023 Filed May 26, 2023 21:53 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001209191-23-032681 · doc4.xml · derivative · entry 1 Senner Christopher J. · CIK 0001648367 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2033-05-23 F1 · derivative.exercise_date: The shares subject to the stock option shall vest in equal annual installments over the three-year period following the grant date of May 24, 2023. Read SEC document |
| May 15, 2023 Filed May 18, 2023 00:16 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 10,002 | $19.18 | $191,838.36 |
DisclosureSEC source: 0000939767-23-000052 · wf-form4_168436898296817.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 571,631 F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded March 4, 2022. Read SEC document |
| May 15, 2023 Filed May 18, 2023 00:16 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 8,444 | $19.18 | $161,955.92 |
DisclosureSEC source: 0000939767-23-000052 · wf-form4_168436898296817.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 581,633 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded March 4, 2021. F2 · balance_after: Includes 190,763 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| April 03, 2023 Filed Apr 6, 2023 00:25 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 85,414 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-23-000038 · wf-form4_168074073189294.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 590,077 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2024 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested. F3 · balance_after: Includes 225,796 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 02:42 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 5,278 | $18.08 | $95,426.24 |
DisclosureSEC source: 0000939767-23-000025 · wf-form4_167668814014763.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,663 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on December 15, 2021. F2 · balance_after: Includes 140,382 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 15, 2022 Filed Nov 18, 2022 01:38 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 8,074 | $16.71 | $134,916.54 |
DisclosureSEC source: 0000939767-22-000111 · wf-form4_166873549446307.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 509,941 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 11, 2020, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on September 30, 2021. F2 · balance_after: Includes 150,128 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.